“Academic medical experts, senior leaders from the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), highly experienced drug developers, and other specialists will come together to discuss LGMD pathophysiology, clinical outcomes and patient-focused drug development, surrogate endpoints and the accelerated approval pathway. The meeting will focus on six LGMD subtypes: LGMD2A/R1, LGMD2B/R2, LGMD2C/R3, LGMD2D/R4, LGMD2E/R5, and LGMD2I/R9.”
The meeting will be held virtually and by invitation for in-person attendance
. Proceedings will be recorded and shared with the broader patient and scientific communities through The Speak Foundation.